Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

7,964 total articles

World Bank Sets Sights on $6 Billion in Concessional Support for Mozambique

World Bank Sets Sights on $6 Billion in Concessional Support for Mozambique

The World Bank intends to provide Mozambique with $6 billion in principally concessional finance for public investment projects across the next five years, aiming to combine roughly $3 billion from its balance sheet with $3 billion mobilised externally. Officials also seek an additional $4 billion for private-sector activity while the country faces…

BofA Lowers Dell Price Target Citing Spike in Memory Costs

BofA Lowers Dell Price Target Citing Spike in Memory Costs

Bank of America reduced its price target for Dell Technologies to $135 from $150, while maintaining a Buy rating. The cut reflects a sharp rise in memory prices that the bank says could materially pressure Dell's margins and fiscal 2027 earnings, though analysts caution the projected impacts are upper-bound estimates and may be mitigated by cost an…

Novo Nordisk’s CagriSema trails Lilly’s Zepbound in head-to-head trial, analysts say M&A may be next focus

Novo Nordisk’s CagriSema trails Lilly’s Zepbound in head-to-head trial, analysts say M&A may be next focus

Novo Nordisk’s experimental obesity drug CagriSema underperformed Eli Lilly’s Zepbound in a direct comparison, prompting analysts to question Novo’s path to regain its early lead in the obesity drug market. Industry strategists say the trial result amplifies commercial uncertainty and could push investor attention to potential M&A moves to shore up…

Allurion Gains After FDA Clears Swallowable Gastric Balloon System

Allurion Gains After FDA Clears Swallowable Gastric Balloon System

Shares of Allurion Technologies jumped 40% after U.S. Food and Drug Administration approval of the Allurion Gastric Balloon System, which includes the ingestible Allurion Smart Capsule. The approval covers treatment for adults with a body mass index of 30 to 40 kg/m2, potentially addressing roughly 80 million Americans in that range, according to t…

Bank of America Sees Ruling on IEEPA Tariffs as Clear Tailwind for Parts of SMID E-commerce, Names Etsy as Top Beneficiary

Bank of America Sees Ruling on IEEPA Tariffs as Clear Tailwind for Parts of SMID E-commerce, Names Etsy as Top Beneficiary

Bank of America analysts say the Supreme Court's decision to invalidate the IEEPA-based tariffs has delivered a notable positive shock to portions of the small- and mid-cap e-commerce universe. Shares in the group rallied after the ruling but pared gains when a new global tariff under Section 122 was announced. Within the sector, Etsy is singled ou…

TOP Ships to Buy Nine ECO MR Tanker Newbuilds in $679M Backlog Deal

TOP Ships to Buy Nine ECO MR Tanker Newbuilds in $679M Backlog Deal

TOP Ships Inc. (NASDAQ:TOPS) said it will acquire nine special purpose companies that hold shipbuilding contracts for ECO MR product/chemical tankers, in a deal that carries a potential gross revenue backlog of about $679 million. The transaction, with an entity affiliated with the company's CEO as seller, includes secured time charter employment s…

Markets Gain as Supreme Court Ruling Dampens Tariff Fears; Nvidia Earnings Take Center Stage

Markets Gain as Supreme Court Ruling Dampens Tariff Fears; Nvidia Earnings Take Center Stage

U.S. equity benchmarks closed higher on Friday after the Supreme Court curtailed much of President Trump's tariff program, a move that could ease cost pressures for businesses. The S&P 500, Nasdaq and Dow all posted gains for the day and week, while attention shifts to Nvidia's upcoming earnings and a docket of economic reports due in the coming da…

MoonLake Shares Rise After Positive Phase 2 axSpA Data for Sonelokimab

MoonLake Shares Rise After Positive Phase 2 axSpA Data for Sonelokimab

MoonLake Immunotherapeutics saw its stock climb in premarket trading after disclosing topline results from the Phase 2 S-OLARIS study of sonelokimab in axial spondyloarthritis (axSpA). The data showed high rates of clinical response at Week 12, corroborated by PET and MRI imaging, while the safety profile remained consistent with earlier studies. T…